Technical Analysis for RCUS - Arcus Biosciences, Inc.

Grade Last Price % Change Price Change
D 17.22 -9.27% -1.76
RCUS closed down 9.27 percent on Monday, March 18, 2024, on approximately normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Flat Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 200 DMA Bearish 0.00%
Crossed Above 20 DMA Bullish -9.27%
Pocket Pivot Bullish Swing Setup -9.27%
Fell Below 20 DMA Bearish -6.00%
200 DMA Support Bullish -6.00%
Gapped Down Weakness -6.00%
NR7 Range Contraction -9.61%
Inside Day Range Contraction -7.62%
Wide Bands Range Expansion -7.62%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 15 hours ago
Fell Below 200 DMA about 15 hours ago
200 DMA Support about 16 hours ago
Down 5% about 16 hours ago
Fell Below Previous Day's Low about 16 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Arcus Biosciences, Inc. Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1

Is RCUS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 25.47
52 Week Low 12.96
Average Volume 917,553
200-Day Moving Average 18.04
50-Day Moving Average 17.15
20-Day Moving Average 18.69
10-Day Moving Average 18.53
Average True Range 1.03
RSI (14) 45.05
ADX 25.68
+DI 20.88
-DI 20.09
Chandelier Exit (Long, 3 ATRs) 17.21
Chandelier Exit (Short, 3 ATRs) 19.03
Upper Bollinger Bands 20.65
Lower Bollinger Band 16.72
Percent B (%b) 0.13
BandWidth 20.99
MACD Line 0.35
MACD Signal Line 0.54
MACD Histogram -0.1898
Fundamentals Value
Market Cap 1.55 Billion
Num Shares 90.1 Million
EPS -4.00
Price-to-Earnings (P/E) Ratio -4.31
Price-to-Sales 11.87
Price-to-Book 2.74
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.95
Resistance 3 (R3) 20.23 19.61 19.50
Resistance 2 (R2) 19.61 18.91 19.47 19.34
Resistance 1 (R1) 18.41 18.48 18.10 18.13 19.19
Pivot Point 17.79 17.79 17.63 17.65 17.79
Support 1 (S1) 16.59 17.09 16.28 16.31 15.25
Support 2 (S2) 15.97 16.66 15.83 15.10
Support 3 (S3) 14.77 15.97 14.95
Support 4 (S4) 14.49